Introduction
Thalassaemia stands as one of the most common inherited blood disorders, impacting males and females equally worldwide.1 This condition follows an autosomal recessive pattern,2 stemming from abnormal gene mutations that lead to reduced or absent production of alpha (α) or beta (β) globin chains, resulting in either alpha (α) or beta (β) thalassaemia.3
Individuals with Cooley’s anaemia, known as β-thalassaemia (major), typically present severe clinical symptoms, requiring lifelong red blood cell transfusions and chelation therapy to manage iron overload. Conversely, beta-thalassaemia intermedia or Mediterranean anaemia often does not require transfusions but may show signs of anaemia and iron overload later in life.4 Those with beta-thalassaemia minor or carriers usually remain clinically asymptomatic.
Beta-thalassaemia is predominantly prevalent in regions like the Mediterranean, Italy, Greece, Africa, the Middle East, the Far East and South Asian countries.2 Its occurrence is not common in North America and Europe.5 Asia has the highest prevalence, comprising 95% of α-thalassaemia and β-thalassaemia births in Southeast Asia.6 Low-income and middle-income countries witness an estimated 50 000–100 000 deaths annually due to this condition.7 8 In Middle Eastern Asian countries like Iraq, Jordan, Lebonan, Saudi Arabia, UAE, Oman and Qatar,8 consanguineous marriages contribute to high beta thalassemia carrier rates.5 South and Southeast Asian countries also exhibit high carrier rates, up to 12%.
Thalassemia is a growing public health concern in Pakistan despite being preventable. With a population exceeding 220 million, the country lacks a national thalassemia registry and crucial epidemiological data on its incidence, prevalence and mortality rates regarding thalassaemia and other blood disorders. Estimates suggest a 5%–7% carrier rate, resulting in 8–10 million β-thalassaemia carriers and around 100 000 individuals with beta-thalassaemia major. Annually, 5000–9000 new β-thalassemia cases are added to Pakistan’s population due to a trend of marriages among carriers. Despite improvements in literacy, many remain unaware of the increasing population affected by beta-thalassaemia major.
Social stigma, misconceptions about religious beliefs related to abortions and family marriages, and limited awareness of genetic diseases have exacerbated the problem. Ethnic, social and cultural factors contribute to the high prevalence of transfusion-dependent thalassaemia in Pakistan. Promoting awareness about premarital and antenatal screening appears to be the primary solution to address this.
Pakistan faces challenges in implementing national policies and public programmes for premarital screening, counselling and early detection of thalassaemia in families. Although some provinces have passed laws on premarital screening for thalassaemia, these laws remain largely unimplemented due to government disinterest, lack of public awareness and the cost of screening tests.
The country’s weak health system, limited resources and inadequate accessibility to supportive treatments such as regular transfusions with chelation therapy and multidisciplinary care further compound the issue. Patients with thalassaemia in Pakistan suffer from a significantly reduced life expectancy of 10–12 years, primarily due to complications arising from iron overload and substandard treatment.9–11
The majority of patients with transfusion-dependent thalassaemia come from low socioeconomic backgrounds. Public sector hospitals have limited resources to manage chronic diseases like transfusion-dependent thalassaemia. Welfare organisations and non-governmental organisations, through thalassaemia centres, step in to provide essential services such as monthly transfusions and chelation therapy when required. However, these centres face challenges due to the growing number of patients, with around 5000 new cases annually. Despite their efforts, these centres often fall short of delivering comprehensive care. They are understaffed and lack clinicians and ancillary staff with the expertise needed for optimal management. Most patients receive oral chelation therapy, and only a few with chronic conditions get intravenous chelation therapy, typically administered once or twice a month during their transfusion visits.
Most NGOs offer supportive transfusion services to patients, but only a few provide chelation therapy. For emergency services, patients turn to tertiary hospitals. In Karachi, four NGOs assist patients with regular screenings, hormonal checkups and cardiac health assessments.
The absence of national programmes for thalassaemia guidance, screening and family counselling underscores the necessity to comprehend the experiences of parents and caregivers involved in their children’s lifelong healthcare. Hence, this study aimed to explore the challenges and experiences of parents and family caregivers of children with beta-thalassaemia (major) in Pakistan, identifying the obstacles and facilitators affecting their access to healthcare services.
Understanding parents’ perspectives and lived experiences is crucial for effective interventions, health advocacy and policy improvements in tackling this pressing health issue.